levodopa-carbidopa
Brand: Sinemet, Rytary, Duopa, Inbrija
Prototype Drug
Drug Class: antiparkinsonian
Drug Family: antiparkinsonian
Subclass: dopamine precursor / DOPA decarboxylase inhibitor combination
Organ Systems: cns
Mechanism of Action
Levodopa is the direct precursor to dopamine and crosses the BBB via L-amino acid transporters; carbidopa inhibits peripheral DOPA decarboxylase, preventing conversion of levodopa to dopamine in the periphery (reducing nausea, hypotension) and increasing levodopa availability for CNS conversion.
dopamine synthesis pathwayaromatic amino acid decarboxylase (AAAD/DOPA decarboxylase)
Indications
- Parkinson's disease (gold standard symptomatic treatment)
- restless leg syndrome (off-label)
- dopa-responsive dystonia
Contraindications
- concurrent non-selective MAOIs
- narrow-angle glaucoma
- melanoma (theoretical — dopamine is melanin precursor)
Adverse Effects
Common
- nausea and vomiting (significantly reduced by carbidopa)
- dyskinesias (especially peak-dose with long-term use)
- 'wearing-off' phenomenon
- orthostatic hypotension
- somnolence
Serious
- dyskinesias (peak-dose and biphasic)
- impulse control disorders (gambling, hypersexuality)
- psychosis/hallucinations
- on-off fluctuations
- dopamine agonist withdrawal syndrome (abrupt cessation)
Pharmacokinetics (ADME)
| Absorption | L-amino acid transporter in gut; protein (especially large neutral amino acids) competitively inhibits absorption — take 30–60 min before meals |
| Distribution | Levodopa crosses BBB via L-amino acid transporter; carbidopa does not cross BBB |
| Metabolism | CNS and peripheral DOPA decarboxylase converts levodopa to dopamine; COMT converts to 3-O-methyldopa (blocked by entacapone/tolcapone) |
| Excretion | Renal |
| Half-life | 1–2 hours (levodopa); longer with extended-release formulations |
| Onset | 30–60 minutes |
| Peak | 1–2 hours (IR) |
| Duration | 2–5 hours (IR); 4–6 hours (Rytary ER) |
| Protein Binding | minimal |
| Vd | minimal |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| non-selective MAOIs | hypertensive crisis from excess catecholamines | major |
| dopamine antagonists (antipsychotics, metoclopramide) | block dopamine receptors, directly antagonizing levodopa effect | major |
| high-protein meals | large neutral amino acids compete with levodopa for intestinal absorption and BBB transport | moderate |
Nursing Considerations
- Administer 30–60 minutes before meals; high-protein diets significantly reduce absorption and clinical effect — counsel patient on consistent, moderate protein intake and timing
- Motor fluctuations: document timing of doses and motor function (on/off periods, dyskinesias) to guide dose adjustments; wearing-off typically occurs before next dose
- Instruct patient to change positions slowly — orthostatic hypotension is common especially early in treatment; measure standing BP
- Dyskinesias (involuntary movements) are a sign of excess dopamine at peak levels, not disease worsening — distinguish from tremor; may require dose reduction or adjunctive therapy
Clinical Pearls
- Carbidopa's sole purpose is to block peripheral DOPA decarboxylase — it does not cross the BBB and has no antiparkinsonian effect on its own; it merely allows higher levodopa doses with fewer peripheral side effects
- Levodopa is the most effective antiparkinsonian drug, but long-term use (>5 years) invariably leads to motor complications (wearing-off, dyskinesias) — debate continues about whether delaying levodopa initiation preserves longer honeymoon period
Safety Profile
Pregnancy use-with-caution
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.